Hypoalbuminemia is a surrogate biomarker of poor prognosis in myelodysplastic syndrome even when adjusting for comorbidities

Sevindik O. G., Guc Z., Kahraman S., Solmaz S. M., Katgi A., Acar C., ...Daha Fazla

LEUKEMIA & LYMPHOMA, cilt.56, sa.9, ss.2552-2555, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 56 Sayı: 9
  • Basım Tarihi: 2015
  • Doi Numarası: 10.3109/10428194.2015.1014362
  • Dergi Adı: LEUKEMIA & LYMPHOMA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.2552-2555
  • Anahtar Kelimeler: Myelodysplastic syndrome, albumin, HCT-CI, leukemia-free survival, overall survival, STEM-CELL TRANSPLANTATION, SERUM-ALBUMIN, SCORING SYSTEM, RISK, SURVIVAL, MORTALITY, DISEASE, INDEX, ASSOCIATION, RELEVANCE
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

The serum albumin (SA) level has been reported to be an independent prognostic biomarker that may serve as a surrogate representative of disease biology in patients diagnosed with myelodysplastic syndrome (MDS). However, its prognostic ability has not been tested in a model adjusting for comorbidities. We analyzed 200 patients who were diagnosed as having de novo MDS. Median overall survival (OS) of all patients was 25 months and median leukemia-free survival (LFS) was 24 months. Median OS according to the SA level groups of <= 3.5, 3.6-4.0 and > 4.0 mg/dL were 24, 39 and 77 months, respectively. SA level remained an independent predictor of both LFS and OS even when adjusting for the hematopoietic cell transplant comorbidity index (HCT-CI) and the International Prognostic Scoring System (IPSS) or World Health Organization classification-based Prognostic Scoring System (WPSS). Our findings indicate that SA level at the time of diagnosis is a significant and independent predictor of LFS and OS even when adjusting for commonly used prognostic systems and comorbidities.